Expert Insights

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...

Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.

Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.

Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...

Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.

Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.

Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.